Status:

ENROLLING_BY_INVITATION

Validation of SMS Protocol for HCC Screening in High-risk Patients

Lead Sponsor:

Erasmus Medical Center

Conditions:

Hepatocellular Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

The investigators will assess implementation of the proposed SMS protocol as a surveillance tool in patients at high risk of developing HCC in a prospective multicenter study.

Detailed Description

Over the past 20 years, the prevalence of HCC has been growing extensively. HCC makes up for 75-85% of primary liver cancers and has a poor prognosis with a 5-year survival rate lower than 20%. The in...

Eligibility Criteria

Inclusion

  • Male and female patients above 18 years of age
  • High-risk patients with cirrhosis and/or hepatitis

Exclusion

  • Patients below the age of 18 years
  • Patients who will not sign the informed consent form
  • Patients with general contra-indications for undergoing MRI examination

Key Trial Info

Start Date :

November 7 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2026

Estimated Enrollment :

470 Patients enrolled

Trial Details

Trial ID

NCT05429190

Start Date

November 7 2023

End Date

June 1 2026

Last Update

November 29 2023

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Academic Medical Center

Amsterdam, North Holland, Netherlands, 1105AZ

2

Medisch Spectrum Twente

Enschede, Overijssel, Netherlands, 7512KZ

3

Albert Schweitzer Ziekenhuis

Dordrecht, South Holland, Netherlands, 3318AT

4

Erasmus Medical Center

Rotterdam, South Holland, Netherlands, 3015GD

Validation of SMS Protocol for HCC Screening in High-risk Patients | DecenTrialz